From October 21 to 27, the “13th Five-Year Plan” Scientific and Technological Innovation Achievement Exhibition was held at the Beijing Exhibition Center. CH Biomedical’s CH-VAD, was showcased in the Social Development Section as a representative of China’s high-end medical devices.
“13th Five-Year Plan” Scientific and Technological Innovation Achievement Exhibition, image source: Internet
Hosted by the Ministry of Science and Technology (MOST), the National Development and Reform Commission (NDRC), the Ministry of Finance (MOF), the Equipment Development Department of the CPC Central Military Commission, the Science and Technology Commission of the Central Military Commission, and the People’s Government of Beijing Municipality, the exhibition highlighted China’s major achievements during the 13th Five-Year Plan period. Themed “Innovation-driven Development Toward a Science and Technology Powerhouse”, the Exhibition showcased significant breakthroughs in foundational research, strategic high technologies, and social welfare achieved during the “13th Five-Year Plan”. Notable exhibits ranged from the China Space Station model, the Mars rover, and the Chang’e-5 lunar probe to the deep-sea manned submersible Fendouzhe and as well as other iconic national scientific assets and cutting-edge research facilities. CH Biomedical’s CH-VAD was also featured in the Social Development Section as a showcase of China’s high-end medical devices and garnered significant attention at the exhibition.
CH-VAD is an ultracompact, fully magnetically levitated ventricular assist device (VAD) independently developed for patients with end-stage severe heart failure. It can partially or completely replace the heart’s pumping function to maintain systemic circulation. Heart failure remains a major global medical challenge, particularly in its advanced stages. Current pharmacological treatments and rate-control devices rarely halt disease progression, and heart transplantation is limited by donor shortages. VADs therefore offer a novel treatment option for advanced heart failure, serving as an alternative to transplantation and carrying significant societal impact.
CH-VAD on Display at the Exhibition
Dubbed the “crown jewel” of the cardiovascular industry, VAD technology spans multiple disciplines and demands highly integrated technical expertise. CH Biomedical has pursued breakthroughs in ultracompact, fully magnetically levitated VAD technology since 2008. By leveraging multidisciplinary, multi-tier R&D, the company integrates magnetic levitation, advanced computational fluid dynamics (CFD) optimization, and mechatronics integrated with specialized bearing-drive systems. Following continuous refinements in design, prototyping, extensive testing, and animal studies, the company has achieved comprehensive, systematic innovation. It also leads globally in key performance metrics such as blood compatibility, implantation invasiveness, infection resistance, and overall reliability. Since the 11th Five-Year Plan, CH-VAD R&D has been repeatedly designated as a key project under the National “863” Program and later included in the National Key Research and Development Program, passing each evaluation with outstanding results.
CH-VAD’s appearance at the exhibition affirms the company’s unwavering commitment to independent VAD innovation and highlights the milestones achieved so far. Going forward, the company will continue its extensive R&D efforts, deepen its technological expertise, and seek breakthroughs in pivotal enabling technologies. By doing so, it aims to inject fresh momentum into China’s high-end medical device sector and enhance people’s health and well-being through scientific and technological innovation.
